This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Subjects With Seroconversion and HI Titer ā„1:40 in Children 3 to 17 Years of Age
Timeframe: Day 1 to day 387
Percentage of Subjects With Seroconversion and HI Titer ā„ 1:40 in Adults 18 to 64 Years of Age
Timeframe: Day 1 to day 387